Suche
Mein Konto
New drug Leqembi: Hope for Alzheimer's patients in Trier!
Patient from Trier receives groundbreaking Alzheimer's treatment with Leqembi - hope and challenges in the healthcare system.
New drug Leqembi: Hope for Alzheimer's patients in Trier!
An exciting chapter has opened in Alzheimer's research in recent months. Until now, treatment for this complex disease has been mostly symptomatic, but the approval of the drug Leqembi in Europe in August 2025 is raising hope. As the daily news reported, it is the first drug that not only alleviates the disease, but also directly targets the cause of the disease. This innovative agent aims to slow the progression of Alzheimer's disease, particularly in the early stages.
The first experiences with Leqembi come from a patient who is anonymously known as Lisa B. from Trier. Her doctor gave her the infusion at the Brothers of Mercy Hospital after she was diagnosed with Alzheimer's disease two years ago. Although the effectiveness and cost of Leqembi are controversial, Lisa remains optimistic. She tolerates the medication well, but regular check-ups are necessary to monitor side effects such as chills and increased temperature.
Challenges and costs
A look at the financial aspects of Leqembi shows that the treatment costs an estimated 34,000 euros per patient per year - of which 24,000 euros are for the medication and 10,000 euros for medical services. There may also be additional costs for genetic analyzes and the identification of suitable patients through MRI and cerebrospinal fluid tests. These high expenses pose immense challenges for the healthcare system in Germany. In fact, the treatment may only be successful in 5 to 10 percent of Alzheimer's patients, and then only in the very early stages of the disease.
However, there is encouraging news: recent studies suggest that Leqembi's effects may slow the progression of dementia more and for longer than originally thought. Neurologist Matthias Maschke even reports a possible delay in progress by around six months, which represents a real ray of hope for those affected and their families.
Future research fields
But where are we really in Alzheimer’s research? As the Alzheimer's research explains, the causes of the disease remain diverse and complex, from protein deposits to inflammation to genetic factors. Five priorities have been set for dementia research in 2025: from early detection to the use of antibody drugs to improving patients' quality of life.
We are at a turning point with treatment and awareness of Alzheimer’s. While Leqembi raises hope, it is to be hoped that research will continue to be innovative. Lisa B. shows that optimism and progress can go hand in hand.
For more information regarding infusion therapy and providers, you can also visit the website NICA Infusion Center which helps patients find an infusion center and provides a contact point for specific questions. It will be exciting to see how the situation develops in the coming months and whether these new therapies bring the hoped-for breakthroughs.